Research

Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences

Akouda Patassi, Sihem Benaboud, Dadja Essoya Landoh, M Salou, Anoumou Claver Dagnra, Bayaki Saka, Anne Krivine, Jean-François Meritet, Palokinam Pitché, Dominique Salmon-Ceron

Abstract


Background. No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.

Objective. To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.

Method. This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.

Results. In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p<0.0001). In multivariate analysis, factors associated with HBV DNA load >10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).

Conclusion. The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing.


Authors' affiliations

Akouda Patassi, Service Maladies Infectieuses et Pneumologie CHU Sylvanus Olympio, Lomé, Togo

Sihem Benaboud, Unité de Recherche clinique, GFH Cochin, Paris, France

Dadja Essoya Landoh, Division de l’épidémiologie, Ministère de la santé du Togo, Lomé, Togo

M Salou, Laboratoire de Biologie Moléculaire, BIOLIM, Université de Lomé, Togo

Anoumou Claver Dagnra, Laboratoire de Biologie Moléculaire, BIOLIM, Université de Lomé, Togo

Bayaki Saka, Service de dermatologie et IST, CHU Sylvanus Olympio, Université de Lomé, Togo

Anne Krivine, Laboratoire de Virologie Pr Rozenberg Pöle Biologie Pharmacie Pathologie, Hôpital Cochin, Paris, France

Jean-François Meritet, Laboratoire de Virologie Pr Rozenberg Pöle Biologie Pharmacie Pathologie, Hôpital Cochin, Paris, France

Palokinam Pitché, Service de dermatologie et IST, CHU Sylvanus Olympio, Université de Lomé, Togo; Conseil National de Lutte contre les IST/VIH/Sida, Lomé, Togo

Dominique Salmon-Ceron, Unité de Pathologie infectieuse, Groupe hospitalier Cochin, Paris, France

Full Text

PDF (148KB)

Keywords

Hepatitis; HBV/HIV coinfection; ART resistance; Togo

Cite this article

South African Medical Journal 2016;106(6):634-639. DOI:10.7196/SAMJ.2016.v106i6.10312

Article History

Date submitted: 2015-11-07
Date published: 2016-05-10

Article Views

Abstract views: 1845
Full text views: 959

Comments on this article

*Read our policy for posting comments here